Two-Timing Nanomedicine Rewires Heart Metabolism After a Heart Attack

When a heart attack strikes, the damaged muscle does not simply die at once. Behind the immediate crisis of blocked coronary arteries lies a slower, quieter catastrophe: the heart’s power plants, its mitochondria, spiral into dysfunction, and the delicate metabolic machinery that keeps cardiac cells alive begins to break apart. Now, a team of researchers led by Jue Wang and colleagues at Xiangya Hospital and Central South University in Changsha, China, has unveiled a nanoscale therapeutic designed to intervene at exactly the right moments in that decline. Their work, published in Nature Cardiovascular Research, describes a bioadaptive nanomedicine called NGB—a NAD+–genipin nanomedicine engineered for metabolic balance—that delivers its active ingredients in two carefully timed waves, and in doing so dramatically limits the damage that follows myocardial infarction in rodent models.

The central insight behind NGB is that the pathology of a heart attack is not static; it evolves through distinct phases, each demanding a different therapeutic response. In the earliest hours, injured heart muscle is ravaged by oxidative stress, inflammation, and a wave of programmed cell death driven by failing mitochondria. Later, if the patient survives that acute assault, the long-term story becomes one of metabolic maladaptation: the heart shifts abnormally toward glycolysis, accumulates toxic lipids, suffers acidosis, and loses the ability to generate ATP efficiently through oxidative phosphorylation. Most conventional treatments address only one moment in this timeline. NGB was designed, from the ground up, to span it.

Structurally, NGB is a co-assembled nanoparticle formed from nicotinamide adenine dinucleotide (NAD+), a universal cellular coenzyme essential for redox reactions and energy metabolism, and genipin, a natural plant-derived compound capable of inhibiting the mitochondrial uncoupling protein 2 (UCP2). The researchers first created a pre-crosslinked NAD+–genipin scaffold and then co-assembled it with free NAD+, producing particles whose surface displays clusters of pyridine rings from the NAD+ component. Molecular dynamics simulations revealed the network of hydrogen bonds and pi–pi stacking interactions that hold the structure together, and spectroscopic characterization confirmed the stability of the assembly under physiological conditions, with a gradual degradation profile extending across a full week in simulated bodily environments.

That degradation profile is the heart of the design. When NGB is injected intravenously after an induced heart attack in mice, it preferentially accumulates in the ischemic myocardium—a homing behavior the team verified by tracking fluorescently labeled particles as they concentrated in injured hearts within the first hour and persisted there for days. Once inside cells, the particles respond to the acidic environment of the damaged tissue by releasing an initial burst of free NAD+ within the first three hours. This rapid replenishment restores the NAD+/NADH ratio, buffering cells against the mitochondrial stress, intrinsic apoptosis, and inflammatory signaling that define the early injury phase. Then comes the second act: over the following hours and days, the remaining scaffold provides sustained, mitochondria-associated release of both NAD+ and genipin, maintaining therapeutic exposure precisely where the cell’s energy production takes place.

The temporal precision of this delivery was striking in the team’s measurements. In hypoxic cardiomyocytes treated with NGB, the NAD+/NADH ratio rose in three characteristic phases: a rapid early increase from zero to three hours, a pronounced elevation from three to twelve hours, and a sustained plateau from twelve to twenty-four hours. The same triphasic pattern appeared in the infarct and border regions of living hearts, and it outperformed nicotinamide mononucleotide, a popular NAD+ precursor that failed to achieve comparable sustained intracellular elevations. Docking studies further suggested that NGB particles associate with mitochondrial outer membrane proteins, including the translocase complex TOM and the voltage-dependent anion channel VDAC, positioning the sustained-release depot directly at the doorstep of the mitochondria.

To understand how this staged therapy reshapes cardiac metabolism, the researchers turned to transcriptomics and metabolomics. RNA sequencing of treated hearts revealed a broad restoration of genes governing oxidative metabolism, while metabolomic profiling showed normalized ratios of glycolysis- and acidosis-related metabolites, energy nucleotides, purine intermediates, and medium- and long-chain fatty acids. In essence, NGB appeared to pull the post-infarct heart back from its maladaptive metabolic rewiring—correcting the HIF-1α-driven shift toward anaerobic glycolysis, restraining lactic acid buildup, and re-coordinating the interplay between glucose utilization, fatty-acid beta-oxidation, and mitochondrial respiration.

The mechanistic core of the story lies in two molecular players: sirtuin 1 (SIRT1) and uncoupling protein 2 (UCP2). SIRT1, an NAD+-dependent deacetylase, activates PGC-1α and PPARα, master regulators of mitochondrial oxidative metabolism. By sustaining NAD+ availability, NGB keeps this SIRT1–PGC-1α axis engaged, supporting the heart’s capacity to burn fuel efficiently. UCP2, by contrast, emerged as a pathological culprit: after infarction, its expression climbed persistently, uncoupling oxidative phosphorylation and wasting energy while promoting lipotoxic accumulation. Genipin, delivered in the second therapeutic phase, suppressed this sustained UCP2 upregulation. The team confirmed causality through gain- and loss-of-function experiments: knocking down UCP2 in hypoxic cardiomyocytes and supplementing NAD+ partially reproduced the NGB metabolic phenotype, whereas overexpressing UCP2 or inhibiting SIRT1 reversed distinct components of the respiratory and glycolytic recovery the nanomedicine enables.

Downstream, the consequences cascaded favorably across the injured heart. NGB treatment limited the release of cytochrome c and the intrinsic apoptotic cascade, reduced mitochondrial DNA leakage that would otherwise fuel chronic cGAS–STING-mediated inflammation, and attenuated the fibrotic scarring and ventricular remodeling that convert a single infarct into progressive heart failure. Echocardiography over twenty-eight days showed preserved left ventricular ejection fraction and fractional shortening in treated animals compared with untreated infarct controls, with histological staining revealing thicker infarct walls and smaller fibrotic regions. Dose-optimization studies identified an effective intravenous range, and delayed-treatment experiments confirmed that even later administration retained meaningful benefit. Toxicology screens—spanning blood counts, liver and kidney function markers, and histology of major organs—showed no apparent adverse effects at therapeutic doses.

The broader significance of this work extends beyond a single molecule. NGB exemplifies an emerging philosophy in nanomedicine: that complex, evolving diseases demand therapies whose release kinetics are matched to the temporal structure of the pathology itself. Rather than flooding the body with a static dose of NAD+ or a blunt metabolic drug, the Changsha team engineered a delivery system that behaves almost physiologically—responding to the acidic, damaged microenvironment, homing to the infarct, and staging its intervention in phase with the heart’s own deteriorating and then recovering metabolism. While the findings remain at the preclinical stage in rodents, and translation to human patients will require extensive further testing, the study offers a compelling blueprint for temporally coordinated metabolic intervention after myocardial infarction. For a condition that remains a leading cause of death and long-term disability worldwide, a therapy that not only rescues heart muscle in its darkest hour but also guides its metabolic recovery over the weeks that follow represents a genuinely exciting direction for cardiovascular medicine.

Subject of Research: A bioadaptive NAD+–genipin nanomedicine that delivers staged metabolic therapy to restore mitochondrial function and cardiac performance after myocardial infarction.

Article Title: Bioadaptive spatiotemporal nanomedicine promotes metabolic recovery after myocardial infarction through NAD+ and UCP2 regulation

Article References: Wang, J., Xia, Y., Zheng, W., Yuan, W., Huang, Y., Zhang, Y., Huang, Q., & Ai, K. (2026). Bioadaptive spatiotemporal nanomedicine promotes metabolic recovery after myocardial infarction through NAD+ and UCP2 regulation. Nature Cardiovascular Research. https://doi.org/10.1038/s44161-026-00874-8

Image Credits: AI Generated

DOI: 10.1038/s44161-026-00874-8

Keywords: myocardial infarction, nanomedicine, NAD+, UCP2, mitochondria, SIRT1, cardiac metabolism, ventricular remodeling, genipin, heart failure, oxidative phosphorylation, glycolysis